Binding of [3H]idazoxan and of its methoxy derivative [3H] RX821002 in human fat cells: [3H]idazoxan but not [3H] RX821002 labels additional non-alpha 2-adrenergic binding sites.
Binding studies were carried out in human fat cell membranes with two alpha 2-adrenergic antagonists, [3H]idazoxan and its methoxy derivative [3H]RX821002. Inhibition studies with epinephrine enantiomers indicate that [3H]RX821002 only binds to alpha 2-adrenoceptors, whereas [3H]idazoxan labels alpha 2-adrenoceptors and additional nonadrenergic sites (NAIBS). NAIBS and alpha 2-adrenoceptors display different affinities towards drugs from various chemical families. Imidazoline and some guanidine derivatives exhibit a high affinity for NAIBS. Pharmacological studies of human NAIBS indicate that they are slightly different from those previously reported in the rabbit, suggesting the existence of several subtypes of NAIBS. Furthermore, NAIBS are different from the previously described "imidazoline-preferring sites." [3H]idazoxan and [3H]RX821002 saturation analyses were performed in human adipocytes from different anatomical locations, in order to compare the number of NAIBS and alpha 2-adrenoceptors. Although there was an important variation in NAIBS and alpha 2-adrenoceptor numbers in the studied samples, a very poor correlation was obtained between the Bmax values of the two sites. Moreover, alkylation of alpha 2-adrenoceptors by phenoxybenzamine produces a 90% reduction in accessible [3H]RX821002 binding sites, without modification of [3H]idazoxan binding. These data show that NAIBS are not closely related to the alpha 2-adrenergic molecule. In addition, benextramine appears to be a reversible competitor at NAIBS. [3H]idazoxan binding, but not [3H]RX821002 binding, is sensitive to K+, suggesting that the domains involved in the ligand-NAIBS interaction are different from those involved in the ligand-alpha 2-adrenoceptor interaction.
Langin
D
D
INSERM U317, Institut de Physiologie, Université Paul Sabatier, Toulouse, France.
Paris
H
H
Lafontan
M
M
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000317:Adrenergic alpha-Antagonists / Q000378:metabolism*; D001665:Binding Sites; D000068438:Brimonidine Tartrate; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D003538:Cystamine / Q000494:pharmacology / Q000031:analogs & derivatives; D004146:Dioxanes / Q000378:metabolism*; D004147:Dioxins / Q000378:metabolism*; D004837:Epinephrine / Q000378:metabolism; D005260:Female; D006801:Humans; D019329:Idazoxan / Q000031:analogs & derivatives; D015636:Magnesium Chloride / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011810:Quinoxalines / Q000378:metabolism; D014316:Tritium; D015016:Yohimbine / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D004147:Dioxins; D011810:Quinoxalines; D015636:Magnesium Chloride; D010643:Phenoxybenzamine; D014316:Tritium; D015016:Yohimbine; D000068438:Brimonidine Tartrate; D011189:Potassium Chloride; C029998:benextramine; C058525:2-methoxyidazoxan; D003538:Cystamine; D019329:Idazoxan; D004837:Epinephrine